Growth Metrics

Eli Lilly (LLY) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $40.9 billion.

  • Eli Lilly's Non-Current Debt rose 4072.31% to $40.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $40.9 billion, marking a year-over-year increase of 4072.31%. This contributed to the annual value of $28.5 billion for FY2024, which is 5570.88% up from last year.
  • Per Eli Lilly's latest filing, its Non-Current Debt stood at $40.9 billion for Q3 2025, which was up 4072.31% from $34.2 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Non-Current Debt high stood at $40.9 billion for Q3 2025, and its period low was $14.1 billion during Q3 2022.
  • In the last 5 years, Eli Lilly's Non-Current Debt had a median value of $18.2 billion in 2023 and averaged $21.5 billion.
  • Its Non-Current Debt has fluctuated over the past 5 years, first crashed by 888.14% in 2022, then surged by 6205.12% in 2024.
  • Eli Lilly's Non-Current Debt (Quarter) stood at $15.3 billion in 2021, then fell by 3.97% to $14.7 billion in 2022, then rose by 24.31% to $18.3 billion in 2023, then skyrocketed by 55.71% to $28.5 billion in 2024, then skyrocketed by 43.28% to $40.9 billion in 2025.
  • Its Non-Current Debt stands at $40.9 billion for Q3 2025, versus $34.2 billion for Q2 2025 and $34.5 billion for Q1 2025.